News for Healthier Living

Drug From Stony Brook-Developed Anti-Cancer Compounds Now in Clinical Trials

A promising new cancer chemotherapeutic agent from a taxane class of natural compounds - anti-cancer agents designed to block cell division and trigger the programmed cell death to treat sold tumors - originally developed by researchers at Stony Brook University has entered human clinical trials.

November 5, 2026


November 5 2026

November 4 2026

November 3 2026

November 2 2026

November 1 2026

October 30 2026

October 29 2026

October 28 2026

October 27 2026

October 26 2026

October 25 2026

October 24 2026

October 23 2026